Published October 20, 2018 in Newsweek.
In a controversial move, the U.S. Food and Drug Administration (FDA) is moving toward finalizing the approval of a highly addictive opioid. The decision was made by the FDA’s advisory committee on October 12, where a 10–3 vote occurred in favor of the drug hitting the market.
DSUVIA, the drug in question, is a form of Sufentanil — which is more potent than fentanyl and morphine. It would be sold as an under-the-tongue tablet. While it can treat pain, it’s associated with a high risk for addiction and being dependent upon it. Side effects include but aren’t limited to restlessness, muscle spasms, chest pain and fast heartbeat, according to PubMed Health.
Read the full article.